Literature DB >> 31959056

Identification of a new cryptic PML-RARα fusion gene without t(15;17) and biallelic CEBPA mutation in a case of acute promyelocytic leukemia: a case detected only by RT-PCR but not cytogenetics and FISH.

Zhanglin Zhang1, Yawen Xu2, Mei Jiang1, Fancong Kong2, Zhiwei Chen2, Shuyuan Liu1, Fei Li2.   

Abstract

Acute promyelocytic leukemia (APL) is characterized by the presence of promyelocytic leukemia-retinoic acid receptor α (PML-RARα) fusion gene, which is formed following the specific chromosomal translocation t(15;17)(q22;q21). However, cases with PML-RARα generated by occult t(15;17) which are negative by both cytogenetics and fluorescence in situ hybridization (FISH), are difficult to diagnose, leading to impaired treatment effectiveness. In the present study, we reported a case of a 66-year-old male patient, and bone marrow morphology, flow cytometry and cytogenetics did not support the diagnosis of APL. Molecular techniques, such as reverse-transcription polymerase chain reaction (RT-PCR), showed the existence of a cryptic PML-RARα fusion gene, and sequence analysis revealed a new variable isoform. Hotspot gene mutation analysis showed a biallelic CEBPA mutation. He received IA chemotherapy and all-trans retinoic acid (ATRA) treatment, and finally achieved complete remission. This case report provided valuable insights into the relevance of the correct identification of atypical PML-RARα fusion gene and biallelic CEBPA mutation. Moreover, combination of IA chemotherapy and ATRA treatment suggested a good clinical effect in this atypical PML-RARα.

Entities:  

Keywords:  APL; Biallelic CEBPA mutation; Cryptic PML-RARα; Cytogenetics; FISH; RT-PCR

Mesh:

Substances:

Year:  2020        PMID: 31959056      PMCID: PMC7515521          DOI: 10.1080/15384047.2019.1702398

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  28 in total

1.  NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.

Authors:  Patricia Rubio; B Campos; J A Digiorge; M S Gallego; A Medina; J G Rossi; M S Felice; C N Alonso
Journal:  Int J Hematol       Date:  2016-07-19       Impact factor: 2.490

2.  Identification of PML-RARA rearrangement by RT-PCR and sequencing in an acute promyelocytic leukemia without t(15;17) on G-banding and FISH.

Authors:  Jin-Yeong Han; Kyong-Eun Kim; Kyeong-Hee Kim; Joo-In Park; Jae-Seok Kim
Journal:  Leuk Res       Date:  2006-06-21       Impact factor: 3.156

3.  Acute promyelocytic leukemia with i(17)(q10) on G-banding and PML/RARA rearrangement by RT-PCR without evidence of PML/RARA rearrangement on FISH.

Authors:  Jungwon Huh; H Moon; H Chi; W Chung
Journal:  Int J Lab Hematol       Date:  2008-02-19       Impact factor: 2.877

4.  Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.

Authors:  D Martínez-Cuadrón; P Montesinos; E Vellenga; T Bernal; O Salamero; A Holowiecka; S Brunet; C Gil; C Benavente; J M Ribera; M Pérez-Encinas; J De la Serna; J Esteve; V Rubio; J González-Campos; L Escoda; M E Amutio; M Arnan; J Arias; S Negri; B Lowënberg; M A Sanz
Journal:  Leukemia       Date:  2017-06-06       Impact factor: 11.528

5.  Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.

Authors:  Bas J Wouters; Bob Löwenberg; Claudia A J Erpelinck-Verschueren; Wim L J van Putten; Peter J M Valk; Ruud Delwel
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

6.  CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation.

Authors:  Sonja Röhrs; Michaela Scherr; Julia Romani; Margarete Zaborski; Hans G Drexler; Hilmar Quentmeier
Journal:  J Hematol Oncol       Date:  2010-04-14       Impact factor: 17.388

7.  Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach.

Authors:  Won Kyung Kwon; Jin Young Lee; Yeung Chul Mun; Chu Myong Seong; Wha Soon Chung; Jungwon Huh
Journal:  Korean J Hematol       Date:  2010-09-30

Review 8.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

Review 9.  A previously uncharacterized gene, PML, is fused to the retinoic acid receptor alpha gene in acute promyelocytic leukaemia.

Authors:  A D Goddard; J Borrow; E Solomon
Journal:  Leukemia       Date:  1992       Impact factor: 11.528

Review 10.  All-trans-retinoic acid treatment and retinoic acid receptor alpha gene rearrangement in acute promyelocytic leukemia: a model for differentiation therapy.

Authors:  L Degos
Journal:  Int J Cell Cloning       Date:  1992-03
View more
  2 in total

1.  [Acute promyelocytic leukemia with PML cryptic breakpoint t (15; 17) (q22; q21) negative: a case report and literatures review].

Authors:  C Y Wu; Y L Li; X Y Dong; L Zhang; B J Shang; W Cheng; Z F Huang; Z M Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-01-14

Review 2.  Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene.

Authors:  Alessandro Liquori; Mariam Ibañez; Claudia Sargas; Miguel Ángel Sanz; Eva Barragán; José Cervera
Journal:  Cancers (Basel)       Date:  2020-03-08       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.